Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPY4R | P50391 | 15/20 | 0.45 |
| ▸ | NPY1R | P25929 | 9/20 | 0.45 |
| ▸ | NPY5R | Q15761 | 8/20 | 0.45 |
| ▸ | NPY2R | P49146 | 5/20 | 0.45 |
| ▸ | CTSK | P43235 | 1/20 | 0.40 |
| ▸ | ANPEP | P15144 | 3/20 | 0.38 |
| ▸ | RNPEP | Q9H4A4 | 2/20 | 0.38 |
| ▸ | DNPEP | Q9ULA0 | 2/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1394656 | 1.00 | NPY4R (0.45) | NPY4RNPY1RNPY5RNPY2RCTSK | |
| SCHEMBL16566054 | 1.00 | NPY4R (0.45) | NPY4RNPY1RNPY5RNPY2RCTSK | |
| SCHEMBL16565958 | 1.00 | NPY4R (0.45) | NPY4RNPY1RNPY5RNPY2RCTSK | |
| Hydrochloric Acid SCHEMBL11142131 | 0.99 | NPY4R (0.44) | NPY4RNPY1RNPY5RNPY2RCTSK | |
| SCHEMBL13724544 | 0.94 | NPY4R (0.52) | NPY4RNPY1RNPY5RNPY2R | |
| SCHEMBL1818349 | 0.94 | NPY4R (0.52) | NPY4RNPY1RNPY5RNPY2R | |
| SCHEMBL17866995 | 0.93 | NPY4R (0.41) | NPY4RNPY1RNPY5RNPY2RCTSK | |
| SCHEMBL17866998 | 0.93 | NPY4R (0.41) | NPY4RNPY1RNPY5RNPY2RCTSK | |
| SCHEMBL4890602 | 0.91 | NPY4R (0.40) | NPY4RNPY1RNPY5RNPY2RCTSK | |
| SCHEMBL17866904 | 0.90 | NPY4R (0.40) | NPY4RNPY1RNPY5RNPY2RCTSK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080200399-A1 | Compounds for Treating Neurologic Diseases, Otologic Diseases, or Ophthalmologic Diseases and Methods of Use Thereof | PROTOR PHARMA CORP. | 2008-08-21 | — | — | US | claimed |
| US-20080039531-A1 | Compositions, and kits comprising targeted aldehyde or acetal protease inhibitor compounds for treating muscle disorders | STRACHER ALFRED | 2008-02-14 | — | — | US | claimed |
| EP-1805207-A1 | TREATMENT OF TRAUMATIC OR DEGENERATIVE NEUROLOGIC, OTOLOGIC, OR OPHTHALMOLOGIC DISEASES WITH TARGETED PROTEASE INHIBITORS | Ceptor Corporation (US) | 2007-07-11 | — | — | EP | claimed |
| WO-2006037133-A1 | TREATMENT OF TRAUMATIC OR DEGENERATIVE NEUROLOGIC, OTOLOGIC, OR OPHTHALMOLOGIC DISEASES WITH TARGETED PROTEASE INHIBITORS | CEPTOR CORPORATION (US) | 2006-04-06 | — | — | WO | claimed |
| WO-2005124563-A2 | COMPOUNDS AND KITS FOR TREATING MUSCLE DISORDERS AND METHODS OF USE THEREOF | CEPTOR CORPORATION (US) | 2005-12-29 | — | — | WO | claimed |
| EP-0279887-B1 | Carnitine directed pharmaceutical agents and their use for the manufacture of a medicament for the treatment of muscle disorder | STRACHER ALFRED (US) | 1995-02-01 | — | — | EP | claimed |
| US-4866040-A | DRUG COVALENTLY BONDED TO AMINOCARNITINE FOR DELIVERY TO SPECI FIC SITES | CEPTOR CORPORATION | 1989-09-12 | — | — | US | claimed |
| EP-0279887-A2 | Carnitine directed pharmaceutical agents and their use for the manufacture of a medicament for the treatment of muscle disorder | Stracher, Alfred (US) | 1988-08-31 | — | — | EP | claimed |
| JP-55037185-A | — | — | None | — | — | JP | disclosed |
| JP-57054157-A | — | — | None | — | — | JP | disclosed |
| US-8729024-B2 | Targeted delivery of pharmaceutical compounds | The Resesarch Foundation of State University of New York (US) | 2014-05-20 | — | — | US | disclosed |
| US-20120135915-A1 | TREATMENT OF TRAUMATIC OR DEGENERATIVE NEUROLOGIC, OTOLOGIC, OR OPHTHALMOLOGIC DISEASES WITH TARGETED PROTEASE INHIBITORS | PROTOR PHARMA CORP. | 2012-05-31 | — | — | US | disclosed |
| US-7968516-B2 | Taurine, cysteic acid residue and residue of a protease or calpain inhibitor; directly, indirectly bonded to each other;leucyl argininal residues in form of aldehyde; effective to inhibit calpains; acetal prodrug residues can be converted to the aldehyde form before, during, or after administration | ProTor Pharma Corporation (US) | 2011-06-28 | — | — | US | disclosed |
| US-20090227522-A1 | Targeted Delivery of Pharmaceutical Compounds | THE RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK | 2009-09-10 | — | — | US | disclosed |
| EP-0279887-A2 | Carnitine directed pharmaceutical agents and their use for the manufacture of a medicament for the treatment of muscle disorder | Stracher, Alfred (US) | 1988-08-31 | — | — | EP | disclosed |
| US-4525465-A | PYROGLUTAMYL-LYSYL-LEUCYL-ARGININAL COVALENTLY BONDED TO A SUPPORT | NIPPON KAYAKU KABUSHIKI KAISHA (JP) | 1985-06-25 | — | — | US | disclosed |
| US-4401594-A | PROTEOLYTIC ENZYME INHIBIJTORS; CARDIOVASCULAR AND MUSCULAR DISORDERS | NIPPON KAYAKU KABUSHIKI KAISHA (JP) | 1983-08-30 | — | — | US | disclosed |
| JP-S5754157-A | L-ARGININAL DERIVATIVE AND ITS PREPARATION | NIPPON KAYAKU CO LTD | 1982-03-31 | — | — | JP | disclosed |
| JP-S5537185-A | SUBSTANCE BEARING ADSORBED PROTEASE, ITS PREPARATION AND PREPARATION OF HIGH-PURITY PROTEASE THEREFROM | NIPPON KAYAKU CO LTD | 1980-03-15 | — | — | JP | disclosed |
| JP-S05754157-A | — | — | 0001-01-01 | — | — | JP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120135915-A1 | TREATMENT OF TRAUMATIC OR DEGENERATIVE NEUROLOGIC, OTOLOGIC, OR OPHTHALMOLOGIC DISEASES WITH TARGETED PROTEASE INHIBITORS | ADAMTS1, PREP, ADAMTS5 | NPY4R 4110/4885NPY1R 3879/4885NPY5R 3551/4885 |
| US-20080200399-A1 | Compounds for Treating Neurologic Diseases, Otologic Diseases, or Ophthalmologic Diseases and Methods of Use Thereof | OTC, CLN6, OAT | NPY4R 2855/4885NPY1R 2641/4885NPY5R 2065/4885 |
| US-20080039531-A1 | Compositions, and kits comprising targeted aldehyde or acetal protease inhibitor compounds for treating muscle disorders | CPT1B, CAPNS1, CAPN1 | NPY4R 4822/4885NPY1R 4767/4885NPY5R 4691/4885 |
| US-20090227522-A1 | Targeted Delivery of Pharmaceutical Compounds | ABCG2, CLTB, APOB | NPY4R 1503/4885NPY1R 1153/4885NPY5R 1305/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.